What changed
$REGN — Develops medicines for serious medical conditions.
🎯 Q1 FY26 | Rev $4B | EPS $9.47 vs $8.90 🟢 | Margin 17.8%
💡 Consensus expects Eylea franchise erosion from biosimilars and slowing Dupixent growth, but Q1 2026 showed 19% revenue growth (to $3.61B), EPS beat by 6.4%, and strong operating cash flow ($1.08B). The market underestimates REGN's pipeline optionality (e.g., high-dose Eylea, pozelimab, and oncology assets) and the durability of Dupixent royalties.
🏢 Business Quality: 8/10 | Valuation: fair
📉 Reward/Risk: Upside 15-20% to $730-$760 (pipeline catalysts + earnings momentum) vs downside 10-15% to $540-$570 (biosimilar erosion, pipeline failure). Ratio ~1.5:1.
🔮 Catalyst: Upcoming FDA decisions on high-dose Eylea (Q3 2026) and pozelimab (Q4 2026) for rare diseases; Phase 2/3 data for oncology assets (e.g., REGN5678) at medical conferences (ASCO, ESMO).
Also in play: $AMGN $BIIB $VRTX $GILD $JNJ $LONN